Chinese medical authorities have declared that the anti-flu medicine used in Japan appears to be more effective for COVID-19 patients.
Director of China’s National Center for biotechnology development, Zhang Xinmin said that Japanese medicine called Avigan had produced positive outcomes.
Favipiravir, the active ingredient in a Japanese anti-flu medicine called Avigan, was checked on 340 patients with the COVID-19 in China. Patients who were treated with this drug were recovered quickly. The COVID-19 patients showed greater lung improvement compared to the patients not given the drug.
It is believed that the drug prevents the virus from replicating in the body. It is also revealed that medicine is not useful for patients with severe illness.
Currently, there is no treatment for coronavirus. It has infected 206,852 and killed 8,272 around the globe. The death rate is 9.07% and the recovery rate is 90.93%.
Patients who were given the medicine in Shenzhen had negative results for the coronavirus an average of four days after being diagnosed.